Bong-Ha Shin1, Matthew J Everly2, Hao Zhang1, J Choi3, Ashley Vo3, Xiaohai Zhang4, Edmund Huang3, Stanley C Jordan3, Mieko Toyoda1. 1. Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA. 2. Terasaki Research Institute, Los Angeles, CA. 3. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA. 4. HLA and Immunogenetics Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
BACKGROUND: Chronic antibody-mediated rejection (cAMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We recently reported on clinical use of tocilizumab (TCZ) for treatment of cAMR in HLA-sensitized kidney transplant patients. IgG1 and IgG3 subclasses of IgG are potent effectors of complement- and antibody-dependent cellular cytotoxicity, which are critical mediators of AMR. Here, we examined the impact of TCZ treatment for cAMR on total IgG, IgG1-4 subclasses, and anti-HLA-IgG (total and subclasses). METHODS: Archived plasma obtained pre- and post-TCZ treatment (8 mg/kg, 6×, monthly) from 12 cAMR patients who failed standard of care treatment with intravenous immune globulin + rituximab with or without plasma exchange were tested for total IgG and IgG1-4 by ELISA, anti-HLA-total IgG, IgG3 and IgG4, and donor-specific antibody by Luminex assay. Archived plasma from 14 cAMR patients treated with the standard of care were included as controls. RESULTS: Total IgG and IgG1-3 were significantly reduced post-TCZ, whereas no reduction was seen post-treatment in the control group. Of 11 patients, 8 (73%) showed reduction of anti-HLA-total IgG and IgG3 post-TCZ, but this was not statistically significant. CONCLUSIONS: TCZ reduced total IgG and IgG1-3 and anti-HLA-total IgG and IgG3 levels, suggesting that TCZ suppresses Ig production in B cells nonspecifically, likely through inhibition of interleukin 6-mediated signaling to B cells and plasma cells. This may be a contributing factor for the beneficial effect of TCZ on cAMR observed in this patient population.
BACKGROUND: Chronic antibody-mediated rejection (cAMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We recently reported on clinical use of tocilizumab (TCZ) for treatment of cAMR in HLA-sensitized kidney transplantpatients. IgG1 and IgG3 subclasses of IgG are potent effectors of complement- and antibody-dependent cellular cytotoxicity, which are critical mediators of AMR. Here, we examined the impact of TCZ treatment for cAMR on total IgG, IgG1-4 subclasses, and anti-HLA-IgG (total and subclasses). METHODS: Archived plasma obtained pre- and post-TCZ treatment (8 mg/kg, 6×, monthly) from 12 cAMR patients who failed standard of care treatment with intravenous immune globulin + rituximab with or without plasma exchange were tested for total IgG and IgG1-4 by ELISA, anti-HLA-total IgG, IgG3 and IgG4, and donor-specific antibody by Luminex assay. Archived plasma from 14 cAMR patients treated with the standard of care were included as controls. RESULTS: Total IgG and IgG1-3 were significantly reduced post-TCZ, whereas no reduction was seen post-treatment in the control group. Of 11 patients, 8 (73%) showed reduction of anti-HLA-total IgG and IgG3 post-TCZ, but this was not statistically significant. CONCLUSIONS:TCZ reduced total IgG and IgG1-3 and anti-HLA-total IgG and IgG3 levels, suggesting that TCZ suppresses Ig production in B cells nonspecifically, likely through inhibition of interleukin 6-mediated signaling to B cells and plasma cells. This may be a contributing factor for the beneficial effect of TCZ on cAMR observed in this patient population.
Authors: Konstantin Doberer; Michael Duerr; Philip F Halloran; Farsad Eskandary; Klemens Budde; Heinz Regele; Jeff Reeve; Anita Borski; Nicolas Kozakowski; Roman Reindl-Schwaighofer; Johannes Waiser; Nils Lachmann; Sabine Schranz; Christa Firbas; Jakob Mühlbacher; Georg Gelbenegger; Thomas Perkmann; Markus Wahrmann; Alexander Kainz; Robin Ristl; Fabian Halleck; Gregor Bond; Edward Chong; Bernd Jilma; Georg A Böhmig Journal: J Am Soc Nephrol Date: 2020-12-18 Impact factor: 10.121
Authors: Mélanie Daligault; Béatrice Bardy; Johan Noble; Anne Bourdin; Dominique Masson; Hamza Naciri Bennani; Mathilde Bugnazet; Paolo Malvezzi; Lionel Rostaing; Thomas Jouve Journal: Transplant Direct Date: 2021-04-22